Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal CancerGlobeNewsWire · 5 days ago 
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research · Sep 21, 2026 
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business UpdateGlobeNewsWire · Sep 21, 2026 
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 1, 2026 
16,500 Shares in AnaptysBio, Inc. $ANAB Bought by Canada Pension Plan Investment BoardDefense World · Sep 1, 2026 
GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal CancerZacks Investment Research · Aug 24, 2026AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 21, 2026 | $5.11 | $5.11 | Beat |
| May 12, 2026 | -$0.32 | -$1.84 | Miss |
| Mar 3, 2026 | $0.89 | $1.58 | Beat |
| Nov 4, 2025 | -$1.06 | $0.52 | Beat |
| Aug 7, 2025 | -$1.50 | -$1.34 | Beat |
| May 5, 2025 | -$1.30 | -$1.28 | Beat |
